from an article by Money Marketing 5th march 2012
"Four fund managers discuss their investment strategies in the Asia Pacific market and reveal the sectors offering good value now and the ones with growth potential for the longer term"...
’Some companies are well placed to take significant market share’...
"In Australia, we favour stem cell company Mesoblast. Although its products are still in development, they have the potential to revolutionise treatments for a vast range of diseases and conditions such as heart failure, back pain and diabetes."
Caroline Keen is alternate manager of the Newton Asian income fund
re:newton's law (of investing )!!
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.15 |
Change
0.045(4.07%) |
Mkt cap ! $1.313B | |||
| Open | High | Low | Value | Volume |
| $1.08 | $1.16 | $1.08 | $4.681M | 4.170M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 99680 | $1.15 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.16 | 31000 | 2 |
View Market Depth
| Last trade - 16.10pm 19/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |